
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8829654/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Worsening renal function in acute heart failure in the context of diuretic response. European Journal of Heart Failure, 2022, 24, 365-374.	7.1	34
2	Hemodynamic profiles by non-invasive monitoring of cardiac index and vascular tone in acute heart failure patients in the emergency department: External validation and clinical outcomes. PLoS ONE, 2022, 17, e0265895.	2.5	3
3	Troponin is unrelated to outcomes in heart failure patients discharged from the emergency department. Journal of the American College of Emergency Physicians Open, 2022, 3, e12695.	0.7	2
4	Current Emergency Department Disposition of Patients With Acute Heart Failure: An Opportunity for Improvement. Journal of Cardiac Failure, 2022, 28, 1545-1559.	1.7	5
5	Comparison of Dyspnea Measurement Instruments in Acute Heart Failure: The DYSPNEA-AHF Pilot Study. Journal of Cardiac Failure, 2021, 27, 607-609.	1.7	1
6	Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department. JAMA Cardiology, 2021, 6, 200.	6.1	18
7	Effects of a Novel Nitroxyl Donor in Acute HeartÂFailure. JACC: Heart Failure, 2021, 9, 146-157.	4.1	17
8	Analysis of standards of quality for outcomes in acute heart failure patients directly discharged home from emergency departments and their relationship with the emergency department direct discharge rate. Journal of Cardiology, 2021, 77, 245-253.	1.9	8
9	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the <scp>RELAXâ€AHF</scp> â€2 study. European Journal of Heart Failure, 2021, 23, 58-67.	7.1	10
10	2020 expert consensus statement on neuro-protection after cardiac arrest in China. Annals of Translational Medicine, 2021, 9, 175-175.	1.7	6
11	Blood Pressure Reduction in Hypertensive Acute Heart Failure. Current Hypertension Reports, 2021, 23, 11.	3.5	7
12	Prognostic value of lung ultrasound in patients hospitalized for heart disease irrespective of symptoms and ejection fraction. ESC Heart Failure, 2021, 8, 2660-2669.	3.1	22
13	Improvement in Kansas City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007956.	2.2	5
14	Lung Ultrasound–Guided Emergency Department Management of Acute HeartÂFailure (BLUSHED-AHF). JACC: Heart Failure, 2021, 9, 638-648.	4.1	28
15	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute HeartÂFailure. JACC: Heart Failure, 2021, 9, 890-903.	4.1	7
16	Acute Heart Failure. , 2020, , 501-519.		1
17	Effects of serelaxin in patients admitted for acute heart failure: a metaâ€analysis. European Journal of Heart Failure, 2020, 22, 315-329.	7.1	24
18	Cause of Death in Patients With AcuteÂHeartÂFailure. JACC: Heart Failure, 2020, 8, 999-1008.	4.1	12

#	Article	IF	CITATIONS
19	Predictors of emergency medical services use by adults with heart failure; 2009–2017. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 475-480.	1.6	4
20	What are the minimum requirements to establish proficiency in lung ultrasound training for quantifying Bâ€lines?. ESC Heart Failure, 2020, 7, 2941-2947.	3.1	21
21	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAXâ€AHFâ€⊋ trial. European Journal of Heart Failure, 2020, 22, 726-738.	7.1	21
22	Megaâ€ŧrials in heart failure: effects of dilution in examination of new therapies. European Journal of Heart Failure, 2020, 22, 1698-1707.	7.1	11
23	Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure. CJC Open, 2020, 2, 135-144.	1.5	5
24	Diagnostic and Prognostic Utilities of Insulin-Like Growth Factor Binding Protein-7 in Patients With Dyspnea. JACC: Heart Failure, 2020, 8, 415-422.	4.1	13
25	Effects of Serelaxin in Patients with Acute Heart Failure. New England Journal of Medicine, 2019, 381, 716-726.	27.0	174
26	TACIT (High Sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial). Circulation: Heart Failure, 2019, 12, e005931.	3.9	14
27	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLASTâ€AHF trial. European Journal of Heart Failure, 2019, 21, 1561-1570.	7.1	9
28	Limited data to support improved outcomes after community paramedicine intervention: A systematic review. American Journal of Emergency Medicine, 2019, 37, 960-964.	1.6	12
29	Early Treatment in Emergency Department Patients with Acute Heart Failure: Does Time Matter?. Current Heart Failure Reports, 2019, 16, 12-20.	3.3	1
30	ACUTE Heart Failure Risk Stratification. Circulation, 2019, 139, 1157-1161.	1.6	24
31	Vasodilator Therapies in the Treatment of Acute Heart Failure. Current Heart Failure Reports, 2019, 16, 32-37.	3.3	5
32	Bâ€lines in heart failure: will comets guide us?. European Journal of Heart Failure, 2019, 21, 1616-1618.	7.1	2
33	Therapeutic Advances in the Management of Acute Decompensated Heart Failure. American Journal of Therapeutics, 2019, 26, e222-e233.	0.9	10
34	Therapeutic Advances in the Management of Cardiogenic Shock. American Journal of Therapeutics, 2019, 26, e234-e247.	0.9	15
35	Design and rationale of the B-lines lung ultrasound guided emergency department management of acute heart failure (BLUSHED-AHF) pilot trial. Heart and Lung: Journal of Acute and Critical Care, 2019, 48, 186-192.	1.6	18
36	Acute Heart Failure Risk Stratification in the Emergency Department: Are We There Yet?. Revista Espanola De Cardiologia (English Ed), 2019, 72, 190-191.	0.6	1

#	Article	IF	CITATIONS
37	Estratificación del riesgo en pacientes que acuden a urgencias con fallo cardiaco agudo: ¿estamos preparados?. Revista Espanola De Cardiologia, 2019, 72, 190-191.	1.2	1
38	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. International Journal of Cardiology, 2018, 253, 91-96.	1.7	2
39	Mobile integrated health to reduce post-discharge acute care visits: A pilot study. American Journal of Emergency Medicine, 2018, 36, 843-845.	1.6	12
40	What's Next for Acute Heart Failure Research?. Academic Emergency Medicine, 2018, 25, 85-93.	1.8	11
41	Acute Dyspnea and Decompensated Heart Failure. Cardiology Clinics, 2018, 36, 63-72.	2.2	12
42	Optimal Endpoints of Acute Heart Failure Therapy. American Journal of Therapeutics, 2018, 25, e465-e474.	0.9	4
43	The Vulnerable Phase of Heart Failure. American Journal of Therapeutics, 2018, 25, e456-e464.	0.9	25
44	Improving Postdischarge Outcomes in Acute Heart Failure. American Journal of Therapeutics, 2018, 25, e475-e486.	0.9	17
45	Mihai Gheorghiade, MD—Life and Concepts. American Journal of Therapeutics, 2018, 25, e453-e455.	0.9	Ο
46	Design and rationale of a randomized trial: Using short stay units instead of routine admission to improve patient centered health outcomes for acute heart failure patients (SSU-AHF). Contemporary Clinical Trials, 2018, 72, 137-145.	1.8	11
47	Rationale and Design of a Prospective, Multicenter, Observational Study Evaluating Iron Deficiency in Patients Hospitalized for Heart Failure (FERIC-RO). Romanian Journal of Laboratory Medicine, 2018, 26, 271-281.	0.2	1
48	Editor's Choice-The role of the emergency department in the management of acute heart failure: An international perspective on education and research. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 421-429.	1.0	28
49	A multimarker multiâ€time pointâ€based risk stratification strategy in acute heart failure: results from the <scp>RELAXâ€AHF</scp> trial. European Journal of Heart Failure, 2017, 19, 1001-1010.	7.1	81
50	Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Clinical Research in Cardiology, 2017, 106, 444-456.	3.3	8
51	Acute Heart Failure. JACC: Heart Failure, 2017, 5, 329-336.	4.1	29
52	Design and Rationale of a Randomized Trial of a Care Transition Strategy in Patients With Acute Heart Failure Discharged From the Emergency Department. Circulation: Heart Failure, 2017, 10, .	3.9	17
53	Is there a clinically meaningful difference in patient reported dyspnea in acute heart failure? An analysis from URGENT Dyspnea. Heart and Lung: Journal of Acute and Critical Care, 2017, 46, 300-307.	1.6	12
54	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAXâ€AHFâ€2 study. European Journal of Heart Failure, 2017, 19, 800-809.	7.1	104

#	Article	IF	CITATIONS
55	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). European Heart Journal, 2017, 38, 2364-2373.	2.2	102
56	Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. American Heart Journal, 2017, 190, 113-122.	2.7	10
57	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. American Heart Journal, 2017, 187, 62-69.	2.7	9
58	Acute Heart Failure in the Emergency Department: Just a One Night Stand?. Academic Emergency Medicine, 2017, 24, 385-387.	1.8	7
59	Approach to Acute Heart Failure in the Emergency Department. Progress in Cardiovascular Diseases, 2017, 60, 178-186.	3.1	22
60	Rationale and design of the ICON-RELOADED study: International Collaborative of N-terminal pro–B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department. American Heart Journal, 2017, 192, 26-37.	2.7	13
61	Disposition of emergency department patients diagnosed with acute heart failure. European Journal of Emergency Medicine, 2017, 24, 2-12.	1.1	65
62	Breaking the Law of Small Numbers. Circulation: Heart Failure, 2017, 10, .	3.9	1
63	Feasibility of Serial 6-min Walk Tests in Patients with Acute Heart Failure. Journal of Clinical Medicine, 2017, 6, 84.	2.4	5
64	A Historical Perspective on Presentations of Hypertensive Acute Heart Failure. Journal of Cardiovascular Diseases & Diagnosis, 2017, 05, .	0.0	2
65	Design and rationale of the high-sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial. Journal of Pragmatic and Observational Research, 2017, Volume 8, 85-90.	1.5	2
66	Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. Cardiac Failure Review, 2017, 3, 122.	3.0	27
67	Dyspnea Assessment and Airway Management in Acute Heart Failure Patients. Contemporary Cardiology, 2017, , 109-116.	0.1	0
68	Lactate levels as a marker of tissue hypoperfusion in acute heart failure patients seen in the emergency department: a pilot study. Emergency Care Journal, 2016, 1, .	0.3	1
69	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. Academic Emergency Medicine, 2016, 23, 922-931.	1.8	10
70	Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure. Journal of Cardiac Failure, 2016, 22, 781-788.	1.7	24
71	Use of High-Sensitivity Troponin T to IdentifyÂPatients With Acute Heart Failure atÂLowerÂRisk for Adverse Outcomes. JACC: Heart Failure, 2016, 4, 591-599.	4.1	49
72	Digoxin for Worsening Chronic HeartÂFailure. JACC: Heart Failure, 2016, 4, 365-367.	4.1	6

#	Article	IF	CITATIONS
73	The Association Between Use of Brain CT for Atraumatic Headache and 30-Day Emergency Department Revisitation. American Journal of Roentgenology, 2016, 207, W117-W124.	2.2	10
74	Serelaxin in the Treatment of Acute Heart Failure. Current Emergency and Hospital Medicine Reports, 2016, 4, 213-218.	1.5	0
75	ED opioid prescribing is not associated with higher patient satisfaction scores. American Journal of Emergency Medicine, 2016, 34, 2032-2034.	1.6	13
76	Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal, 2016, 178, 198-205.	2.7	14
77	Contextual risk: a study of fish out of water. European Journal of Heart Failure, 2016, 18, 1506-1507.	7.1	0
78	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. Journal of Cardiac Failure, 2016, 22, 618-627.	1.7	4
79	Evaluation of a provocative dyspnea severity score in acute heart failure. American Heart Journal, 2016, 172, 34-41.	2.7	9
80	Cardiac Output Monitoring Managing Intravenous Therapy (COMMIT) to Treat Emergency Department Patients with Sepsis. Shock, 2016, 46, 132-138.	2.1	13
81	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. Clinical Research in Cardiology, 2016, 105, 727-737.	3.3	16
82	Utility of Patient-Reported Outcome Instruments in Heart Failure. JACC: Heart Failure, 2016, 4, 165-175.	4.1	120
83	Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. American Heart Journal, 2015, 170, 1124-1132.	2.7	8
84	Growth differentiation factor 15 (<scp>GDF</scp> â€15) in patients admitted for acute heart failure: results from the <scp>RELAXâ€AHF</scp> study. European Journal of Heart Failure, 2015, 17, 1133-1143.	7.1	86
85	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the <scp>RELAXâ€AHF</scp> study. European Journal of Heart Failure, 2015, 17, 1262-1270.	7.1	110
86	Acute heart failure: the role of focused emergency cardiopulmonary ultrasound in identification and early management. European Journal of Heart Failure, 2015, 17, 1223-1227.	7.1	26
87	Patient Characteristics and Outcomes Associated With Nitrovasodilator Use in the Treatment of Acute Heart Failure. American Journal of Therapeutics, 2015, 22, 206-213.	0.9	0
88	Abdominal Computed Tomography Utilization and 30-day Revisitation in Emergency Department Patients Presenting With Abdominal Pain. Academic Emergency Medicine, 2015, 22, 803-810.	1.8	24
89	Focused Ultrasound In The Emergency Department For Patients With Acute Heart Failure. Cardiac Failure Review, 2015, 1, 83.	3.0	4
90	Heart Failure Therapeutics on theÂBasisÂofÂaÂBiased Ligand of theÂAngiotensin-2 TypeÂ1ÂReceptor. JACC: Heart Failure, 2015, 3, 193-201.	4.1	68

#	Article	IF	CITATIONS
91	Patient preferences regarding medical decision making in the emergency care setting: a pilot-study. American Journal of Emergency Medicine, 2015, 33, 719-721.	1.6	3
92	In response to "Scope of shared decision making in patients with psychologic complaints― American Journal of Emergency Medicine, 2015, 33, 841.	1.6	0
93	Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial. American Heart Journal, 2015, 169, 572-578.e1.	2.7	23
94	The Potential Role of Natriuretic Peptide–Guided Management for Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2015, 21, 233-239.	1.7	16
95	ED operational factors associated with patient satisfaction. American Journal of Emergency Medicine, 2015, 33, 111-112.	1.6	8
96	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions—A Consensus Document from the <scp>SAEM</scp> / <scp>HFSA</scp> Acute Heart Failure Working Group. Academic Emergency Medicine, 2015, 22, 94-112.	1.8	41
97	Revisiting Cardiac Injury During Acute Heart Failure: Further Characterization and a Possible Target for Therapy. American Journal of Cardiology, 2015, 115, 141-146.	1.6	3
98	Lack of evidence for intravenous vasodilators in ED patients with acute heart failure: a systematic review. American Journal of Emergency Medicine, 2015, 33, 133-141.	1.6	44
99	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. Journal of Cardiac Failure, 2015, 21, 27-43.	1.7	73
100	Assessment of Dyspnea Early in Acute Heart Failure: Patient Characteristics and Response Differences Between Likert and Visual Analog Scales. Academic Emergency Medicine, 2014, 21, 659-666.	1.8	26
101	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from <scp>RELAXâ€AHF</scp> . European Journal of Heart Failure, 2014, 16, 1230-1240.	7.1	134
102	Ischemic Electrocardiographic Abnormalities and Prognosis in Decompensated Heart Failure. Circulation: Heart Failure, 2014, 7, 986-993.	3.9	33
103	Emergency Departments, Acute Heart Failure, and Admissions. JACC: Heart Failure, 2014, 2, 278-280.	4.1	21
104	Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH) Tj ETQq0 0 0 r	gBT_/Over 1.6	lock 10 Tf 50 2
105	Quality of Life Assessment for Acute Heart Failure Patients From Emergency Department Presentation Through 30 Days After Discharge: A Pilot Study With the Kansas City Cardiomyopathy Questionnaire. Journal of Cardiac Failure, 2014, 20, 18-22.	1.7	26
106	Airway Management and Assessment of Dyspnea in Emergency Department Patients with Acute Heart Failure. Current Emergency and Hospital Medicine Reports, 2013, 1, 122-125.	1.5	7
107	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Failure Reviews, 2013, 18, 107-122.	3.9	51

108Reply to Letter to the Editor by Shiraishi and colleagues. American Heart Journal, 2013, 166, e47.2.70

#	Article	IF	CITATIONS
109	Large-Volume Hypertonic Saline Therapy in Endurance Athlete withÂExercise-Associated Hyponatremic Encephalopathy. Journal of Emergency Medicine, 2013, 44, 1132-1135.	0.7	19
110	Reply. Journal of the American College of Cardiology, 2013, 61, 2491.	2.8	1
111	Is Hospital Admission for Heart Failure Really Necessary?. Journal of the American College of Cardiology, 2013, 61, 121-126.	2.8	120
112	The role of the emergency department in acute heart failure clinical trials—Enriching patient identification and enrollment. American Heart Journal, 2013, 165, 902-909.	2.7	7
113	Reply to: Decision Algorithms are Needed in Acute Heart Failure in the Emergency Department. Journal of Cardiac Failure, 2013, 19, 147-148.	1.7	0
114	The Challenge of Drug Development in Acute Heart Failure. JACC: Heart Failure, 2013, 1, 442-444.	4.1	3
115	Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. Journal of the American College of Cardiology, 2013, 61, 196-206.	2.8	397
116	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet, The, 2013, 381, 29-39.	13.7	810
117	Treatment of acute heart failure in the emergency department. Expert Review of Cardiovascular Therapy, 2013, 11, 1195-1209.	1.5	3
118	Seeking new heights in acute heart failure syndromes: lessons from ASCEND and EVEREST. European Heart Journal, 2013, 34, 1345-1349.	2.2	3
119	Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. European Heart Journal, 2013, 34, 835-843.	2.2	418
120	Management of Hemorrhage Complicated by Novel Oral Anticoagulants in the Emergency Department. American Journal of Therapeutics, 2013, 20, 300-306.	0.9	18
121	Altered Mental Status in a Young, Healthy Female. American Journal of Therapeutics, 2013, 20, 558-563.	0.9	1
122	Serum aldosterone is associated with mortality and reâ€hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. European Journal of Heart Failure, 2013, 15, 1228-1235.	7.1	51
123	Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. European Journal of Heart Failure, 2013, 15, 1382-1389.	7.1	21
124	Fibrinolysis and Thrombectomy for Massive Pulmonary Embolus. American Journal of Therapeutics, 2013, 20, 576-580.	0.9	0
125	Classification of Patients With Acute Heart Failure Syndromes in the Emergency Department. Circulation: Heart Failure, 2012, 5, 2-5.	3.9	3
126	Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine, 2012, 13, 415-422.	1.5	29

#	Article	IF	CITATIONS
127	The Role of Natriuretic Peptides: From the Emergency Department Throughout Hospitalization. Congestive Heart Failure, 2012, 18, S5-8.	2.0	7
128	Bayesian adaptive trial design in acute heart failure syndromes: Moving beyond the mega trial. American Heart Journal, 2012, 164, 138-145.	2.7	31
129	Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: Findings from the EVEREST Trial. American Heart Journal, 2012, 164, 884-892.e2.	2.7	24
130	Standardized Reporting Criteria for Studies Evaluating Suspected Acute Heart Failure Syndromes in the Emergency Department. Journal of the American College of Cardiology, 2012, 60, 822-832.	2.8	7
131	Patients With Acute Heart Failure in the Emergency Department: Do They All Need to Be Admitted?. Journal of Cardiac Failure, 2012, 18, 900-903.	1.7	33
132	A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90Âdays: analysis from the EVEREST trial. Heart Failure Reviews, 2012, 17, 485-509.	3.9	100
133	Early changes in clinical characteristics after emergency department therapy for acute heart failure syndromes: identifying patients who do not respond to standard therapy. Heart Failure Reviews, 2012, 17, 387-394.	3.9	10
134	Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Preâ€RELAXâ€AHF. European Journal of Heart Failure, 2011, 13, 961-967.	7.1	99
135	Acute Heart Failure Syndromes: Initial Management. Emergency Medicine Clinics of North America, 2011, 29, 675-688.	1.2	2
136	A Review of Phase II Acute Heart Failure Syndromes Clinical Trials. Heart Failure Clinics, 2011, 7, 441-450.	2.1	7
137	Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase. American Heart Journal, 2011, 161, 224-232.	2.7	38
138	Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: Analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Trials. American Heart Journal, 2011, 161, 1067-1072.	2.7	37
139	Rationale, design, and results from RENO-DEFEND 1: A randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. American Heart Journal, 2011, 161, 1012-1023.e3.	2.7	15
140	Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. European Heart Journal, 2011, 32, 2563-2572.	2.2	116
141	Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. Heart, 2011, 97, 1607-1618.	2.9	22
142	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. Circulation: Heart Failure, 2010, 3, 314-325.	3.9	134
143	Pathophysiology of Volume Overload in Acute Heart Failure Syndromes. Congestive Heart Failure, 2010, 16, S1.	2.0	8
144	Examining Emergency Department Communication Through a Staff-Based Participatory Research Method: Identifying Barriers and Solutions to Meaningful Change. Annals of Emergency Medicine, 2010, 56, 614-622.	0.6	36

#	Article	IF	CITATIONS
145	Acute Heart Failure Syndromes: Emergency Department Presentation, Treatment, and Disposition: Current Approaches and Future Aims. Circulation, 2010, 122, 1975-1996.	1.6	239
146	The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. European Heart Journal, 2010, 31, 832-841.	2.2	159
147	International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. European Journal of Heart Failure, 2010, 12, 1253-1260.	7.1	54
148	The current and future management of acute heart failure syndromes. European Heart Journal, 2010, 31, 784-793.	2.2	100
149	Acute Heart Failure Clinical Drug Development: From Planning to Proof of Activity to Phase III. Cardiology, 2010, 116, 292-301.	1.4	11
150	Letter by Pang et al Regarding Article, "Early Deaths in Heart Failure Patients Discharged From the Emergency Department: A Population-Based Analysis― Circulation: Heart Failure, 2010, 3, e22; author reply e23.	3.9	0
151	Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure, 2010, 12. 423-433.	7.1	593
152	National Heart, Lung, and Blood Institute Working Group on Emergency Department Management of Acute Heart Failure. Journal of the American College of Cardiology, 2010, 56, 343-351.	2.8	76
153	Troponin Elevation in Heart Failure. Journal of the American College of Cardiology, 2010, 56, 1071-1078.	2.8	371
154	Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patientâ \in " part 1. Acute Cardiac Care, 2009, 11, 3-42.	0.2	43
155	Initial Emergency Department Systolic Blood Pressure Predicts Left Ventricular Systolic Function in Acute Decompensated Heart Failure. Congestive Heart Failure, 2009, 15, 9-13.	2.0	5
156	Therapy for acute heart failure syndromes. Current Cardiology Reports, 2009, 11, 192-201.	2.9	7
157	The Rationale for an Acute Heart Failure Syndromes Clinical Trials Network. Journal of Cardiac Failure, 2009, 15, 467-474.	1.7	24
158	Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. American Heart Journal, 2009, 157, 957-970.	2.7	48
159	Acute Heart Failure Syndromes in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2009, 53, 254-263.	2.8	124
160	Acute Heart Failure Syndromes. Journal of the American College of Cardiology, 2009, 53, 557-573.	2.8	515
161	Special Cases in Acute Heart Failure Syndromes: Atrial Fibrillation and Wide Complex Tachycardia. Heart Failure Clinics, 2009, 5, 113-123.	2.1	2
162	Effects of tolvaptan on dyspnoea relief from the EVEREST trials. European Heart Journal, 2009, 30, 2233-2240.	2.2	71

#	Article	IF	CITATIONS
163	Acute heart failure syndromes: Potential strategies to improve post-discharge outcomes. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 349-357.	0.9	2
164	Patient perspectives on communication with the medical team: Pilot study using the communication assessment tool-team (CAT-T). Patient Education and Counseling, 2008, 73, 220-223.	2.2	72
165	Beyond Pulmonary Edema: Diagnostic, Risk Stratification, and Treatment Challenges of Acute Heart Failure Management in the Emergency Department. Annals of Emergency Medicine, 2008, 51, 45-57.	0.6	81
166	What Do We Really Know About Neurological Misdiagnosis in the Emergency Department?. Mayo Clinic Proceedings, 2008, 83, 252.	3.0	0
167	A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. European Heart Journal, 2008, 29, 816-824.	2.2	131
168	Acute Heart Failure Treatment. Critical Pathways in Cardiology, 2008, 7, 103-110.	0.5	2
169	Design and Rationale of the URGENT Dyspnea Study: An International, Multicenter, Prospective Study. American Journal of Therapeutics, 2008, 15, 299-303.	0.9	14
170	Rationale and Design of the Hemodynamic, Echocardiographic and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitalized With Heart Failure (HORIZON-HF) Trial. American Journal of Therapeutics, 2008, 15, 231-240.	0.9	16
171	Risk Stratification. Critical Pathways in Cardiology, 2008, 7, 96-102.	0.5	2
172	NEAR-CONTINUOUS, NONINVASIVE BLOOD PRESSURE MONITORING IN THE OUT-OF-HOSPITAL SETTING. Prehospital Emergency Care, 2005, 9, 68-72.	1.8	8
173	Wide complex rhythm and cardiac arrest. Journal of Emergency Medicine, 2004, 26, 197-200.	0.7	6
174	Use of a radial artery compression device for noninvasive, near-continuous blood pressure monitoring in the ED. American Journal of Emergency Medicine, 2004, 22, 474-478.	1.6	16